Challenges, progress and strategies in the search for a cure for HIV

References

[1]  van Sighem, A.I. et al. (2010) de WF. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 24, 1527–1535.
| de WF. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals.Crossref | GoogleScholarGoogle Scholar | 20467289PubMed |

[2]  Dieffenbach, C.W. and Fauci, A.S. (2011) Thirty years of HIV and AIDS: future challenges and opportunities. Ann. Intern. Med. 154, 766–771.
| Thirty years of HIV and AIDS: future challenges and opportunities.Crossref | GoogleScholarGoogle Scholar | 21628350PubMed |

[3]  Eisele, E. and Siliciano, R.F. (2012) Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37, 377–388.
| Redefining the viral reservoirs that prevent HIV-1 eradication.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhtlyltLvN&md5=203b86d4a892ad55d54cb3bfccc14e86CAS | 22999944PubMed |

[4]  Chun, T.W. et al. (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24, 2803–2808.
| Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.Crossref | GoogleScholarGoogle Scholar | 20962613PubMed |

[5]  Chun, T.W. et al. (1995) In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1, 1284–1290.
| In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK2MXpslGhtbg%3D&md5=e9b500822e232e21226cc6073a15bba3CAS | 7489410PubMed |

[6]  Chun, T.W. et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183–188.
| Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK2sXjtF2gtr8%3D&md5=be48a764652ead0d1a93515dfdcaaffaCAS | 9144289PubMed |

[7]  Finzi, D. et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300.
| Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK2sXntlOmsro%3D&md5=2b8a543615a83d2b649dc13afd7805d2CAS | 9360927PubMed |

[8]  Finzi, D. et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512–517.
| Latent infection of CD4⁺ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK1MXivVKksro%3D&md5=141b790dd80d5b783af61b60a39242d7CAS | 10229227PubMed |

[9]  Choudhary, S.K. and Margolis, D.M. (2011) Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 51, 397–418.
| Curing HIV: pharmacologic approaches to target HIV-1 latency.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXisFOju7k%3D&md5=979f6cc7ad3759eac5c751ece7f67a78CAS | 21210747PubMed |

[10]  Pace, M.J. et al. (2012) Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog. 8, e1002818.
| Directly infected resting CD4⁺T cells can produce HIV Gag without spreading infection in a model of HIV latency.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhtFeisrfP&md5=aee55001a148d2530dd243250df2f7d4CAS | 22911005PubMed |

[11]  Chomont, N. et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893–900.
| HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXnsFSit7Y%3D&md5=155b7bc6e9229946056523a0b7b85fc2CAS | 19543283PubMed |

[12]  Ellery, P.J. et al. (2007) The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178, 6581–6589.
| 1:CAS:528:DC%2BD2sXksl2ms7k%3D&md5=a09ced280a1bcae603554804e5a34222CAS | 17475889PubMed |

[13]  Sonza, S. et al. (2001) Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 15, 17–22.
| Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3M3htFChtw%3D%3D&md5=50f890a24776f3ae98218e837749c8a6CAS | 11192864PubMed |

[14]  Churchill, M.J. et al. (2006) Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J. Neurovirol. 12, 146–152.
| Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues.Crossref | GoogleScholarGoogle Scholar | 16798676PubMed |

[15]  Gorry, P.R. et al. (1999) Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev. J. Virol. 73, 352–361.
| 1:CAS:528:DyaK1cXotFSks7g%3D&md5=367c9b407f33c5e469611e1851dd7f65CAS | 9847339PubMed |

[16]  Narasipura, S.D. et al. (2014) Epigenetic regulation of HIV-1 latency in astrocytes. J. Virol. 88, 3031–3038.
| Epigenetic regulation of HIV-1 latency in astrocytes.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXmsVOkurg%3D&md5=3071f38d4bdb5df34fc074264c5197fcCAS | 24352441PubMed |

[17]  Buzon, M.J. et al. (2014) HIV-1 persistence in CD4(+) T cells with stem cell-like properties. Nat. Med. 20, 139–142.
| HIV-1 persistence in CD4(+) T cells with stem cell-like properties.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXmtVeqsg%3D%3D&md5=0befd00e4b5cbdf9e0a331144df71343CAS | 24412925PubMed |

[18]  Ho, Y.C. et al. (2013) Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551.
| Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhs1yrurrI&md5=7cc6d4a02ff1a5519e6400dcb84aee00CAS | 24243014PubMed |

[19]  Chun, T.W. et al. (1998) Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95, 8869–8873.
| Early establishment of a pool of latently infected, resting CD4⁺ T cells during primary HIV-1 infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK1cXkvFalt78%3D&md5=0cb24881d15a92704c9424072c8f0312CAS | 9671771PubMed |

[20]  Ananworanich, J. et al. (2014) Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 28, 1015–20.
| Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXlsF2htL8%3D&md5=c9a7bb76205ff77a9824555bef9d7fc1CAS | 24384692PubMed |

[21]  Siliciano, R.F. and Greene, W.C. (2011) HIV latency. Cold Spring Harb Perspect Med 1, a007096.
| HIV latency.Crossref | GoogleScholarGoogle Scholar | 22229121PubMed |

[22]  Katlama, C. et al. (2013) Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 381, 2109–2117.
| Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXltVGhtL0%3D&md5=c2f5defc72602e1e959c575568828d09CAS | 23541541PubMed |

[23]  Saleh, S. et al. (2007) CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110, 4161–4164.
| CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4⁺ T cells to HIV-1 infection: a novel model of HIV-1 latency.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXotFyj&md5=255ced4d1a24ae31af49ed52a429beaaCAS | 17881634PubMed |

[24]  Evans, V.A. et al. (2013) Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells. PLoS Pathog. 9, e1003799.
| Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4⁺ T cells.Crossref | GoogleScholarGoogle Scholar | 24339779PubMed |

[25]  O’Doherty, U. et al. (2000) Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74, 10 074–10 080.
| Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3cXnsFOltLg%3D&md5=20efd2ecb4186a5462aaa0d06b2c0776CAS |

[26]  Coiras, M. et al. (2009) Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 7, 798–812.
| Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXht1Kqsb7J&md5=99c15a4f37e75564ec19e0ae814acf7cCAS | 19834480PubMed |

[27]  Josefsson, L et al. (2013) The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc. Natl. Acad. Sci. USA 110, E4987–E4996.
| The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXnsV2nsA%3D%3D&md5=0b53eacd08048b2b4e19114efb74bf74CAS | 24277811PubMed |

[28]  Hermankova, M. et al. (2001) HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 286, 196–207.
| HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3MXlsVymtr4%3D&md5=8f8cb0e3dc3bb74dd4f58461f0de5107CAS | 11448283PubMed |

[29]  Fletcher, C.V. et al. (2014) Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl. Acad. Sci. USA 111, 2307–2312.
| Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXisFOksb4%3D&md5=6f8cd1b8c4cfa4144f6239bae5e01e2cCAS | 24469825PubMed |

[30]  Buzón, M.J. et al. (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16, 460–465.
| HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.Crossref | GoogleScholarGoogle Scholar | 20228817PubMed |

[31]  Hatano, H. et al. (2013) Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J. Infect. Dis. 208, 1436–1442.
| Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhs1SisLnP&md5=3dffd5497761f470dec51d0cfff17519CAS | 23975885PubMed |

[32]  Palmer, S. et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 105, 3879–3884.
| Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXjslSiur0%3D&md5=56655235a79d904e6d63219fe99f17ebCAS | 18332425PubMed |

[33]  Bailey, J.R. et al. (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80, 6441–6457.
| Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4⁺ T cells.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XntFWisrc%3D&md5=8e4e9a62733324e119f8c147ea744117CAS | 16775332PubMed |

[34]  Canestri, A. et al. (2010) Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin. Infect. Dis. 50, 773–778.
| Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 20100092PubMed |

[35]  Garvey, L.J. et al. (2009) Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment. AIDS 23, 1443–1444.
| Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment.Crossref | GoogleScholarGoogle Scholar | 19564723PubMed |

[36]  Strain, M.C. et al. (2005) Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J. Virol. 79, 1772–1788.
| Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2MXhtFCjurg%3D&md5=5141bfa991643ad6a9f1fc0535745b8bCAS | 15650202PubMed |

[37]  Thompson, K.A. et al. (2011) Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. Am. J. Pathol. 179, 1623–1629.
| Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXhsVSqtb3J&md5=0a4acfdd4c2c51b409aaaa5cceeb70a8CAS | 21871429PubMed |

[38]  Hütter, G. et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698.
| Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.Crossref | GoogleScholarGoogle Scholar | 19213682PubMed |

[39]  Michael, N.L. et al. (1997) The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 3, 338–340.
| The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK2sXhsFGrur8%3D&md5=a99585f08e7d99f1161fe7abb36afd53CAS | 9055864PubMed |

[40]  Huang, Y. et al. (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2, 1240–1243.
| The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK28Xms1WqurY%3D&md5=92adaa8243f9f750e2b9b7e7e096993fCAS | 8898752PubMed |

[41]  Dean, M. et al. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856–1862.
| Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK28XlvFCrsLY%3D&md5=253c2b27a591c2149b0a0563d934a450CAS | 8791590PubMed |

[42]  Yukl, S.A. et al. (2013) Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9, e1003347.
| Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXpslOhur8%3D&md5=c426590eb1221a2ec362a96e9587c529CAS | 23671416PubMed |

[43]  Allers, K. et al. (2011) Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117, 2791–2799.
| Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXjslOgtL8%3D&md5=941464681c9993467d166cd39f0e29ceCAS | 21148083PubMed |

[44]  Hocqueloux, L. et al. (2013) Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J. Antimicrob. Chemother. 68, 1169–1178.
| Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXlvFWgsro%3D&md5=45c1436457d477495ebd55b7c7d50793CAS | 23335199PubMed |

[45]  Sáez-Cirión, A. et al. (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211.
| Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.Crossref | GoogleScholarGoogle Scholar | 23516360PubMed |

[46]  Goujard, C. et al. (2007) Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res. Hum. Retroviruses 23, 1105–1113.
| Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXhtFarsbrJ&md5=daf31c5d2c7ea3a197d1919d60eb00daCAS | 17919105PubMed |

[47]  Lodi, S. et al. (2012) Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch. Intern. Med. 172, 1252–1255.
| Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.Crossref | GoogleScholarGoogle Scholar | 22826124PubMed |

[48]  Stohr, W. et al. (2013) Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS ONE 8, e78287.
| Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhslWksL7K&md5=04e9670003e9fb87a53bb464c725d2dbCAS | 24205183PubMed |

[49]  Persaud, D. et al. (2013) Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828–1835.
| Absence of detectable HIV-1 viremia after treatment cessation in an infant.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhslGhtb7M&md5=f408ae1b1a976a0a257f6e76b57e15f2CAS | 24152233PubMed |

[50]  Persaud, D. et al. (2014) Virologic control by 1 year of age significantly reduces HIV-1 reservoirs in perinatal infection. 2014 Mar 5.

[51]  ClinicalTrials.gov (2014) U S National Institutes of Health. http://clinicaltrials.gov/ (accessed 8 February 2014).

[52]  Henrich, T.J. et al. (2013) Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J. Infect. Dis. 207, 1694–1702.
| Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXntVOrsLw%3D&md5=67625edaa71e0adf4312c2f66fee79e8CAS | 23460751PubMed |

[53]  Henrich, T.J. et al. (2013) Mathematical modeling of HIV-1 latent reservoir dynamics following hematopoietic stem cell transplantation. 2013 Dec 3.

[54]  Henrich, T.J. et al. (2014) HIV-1 rebound following allogeneic stem cell transplantation and treatment interruption . 2014 Mar 6.

[55]  Carrington, M. et al. (1999) Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum. Mol. Genet. 8, 1939–1945.
| Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DyaK1MXmslelsro%3D&md5=e010ccd867f9e4c1c2709b4a6e50f81dCAS | 10469847PubMed |

[56]  Burke, B.P. et al. (2014) CCR5 as a natural and modulated target for inhibition of HIV. Viruses 6, 54–68.
| CCR5 as a natural and modulated target for inhibition of HIV.Crossref | GoogleScholarGoogle Scholar |

[57]  Zou, S. et al. (2013) Hematopoietic cell transplantation and HIV cure: where we are and what next? Blood 122, 3111–3115.
| Hematopoietic cell transplantation and HIV cure: where we are and what next?Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhslGhtbfO&md5=2813614a5c4d05a023fbfcf8af5aab49CAS | 24009230PubMed |

[58]  Zhen, A. and Kitchen, S. (2014) Stem-cell-based gene therapy for HIV infection. Viruses 6, 1–12.
| Stem-cell-based gene therapy for HIV infection.Crossref | GoogleScholarGoogle Scholar |

[59]  Tebas, P. et al. (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910.
| Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXkt1ehsLk%3D&md5=865da0a8443a419a8a47c21a54180574CAS | 24597865PubMed |

[60]  Mitsuyasu, R.T. et al. (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat. Med. 15, 285–292.
| Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXhvFKjt74%3D&md5=5432a2421a9228dd0f3db7f331178ae6CAS | 19219022PubMed |

[61]  Manjunath, N. et al. (2013) Newer gene editing technologies toward HIV gene therapy. Viruses 5, 2748–2766.
| Newer gene editing technologies toward HIV gene therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXmsVyjsLY%3D&md5=8937069c100586645445bb63acaffeedCAS | 24284874PubMed |

[62]  Choudhary, S.K. and Margolis, D.M. (2011) Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 51, 397–418.
| Curing HIV: pharmacologic approaches to target HIV-1 latency.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXisFOju7k%3D&md5=979f6cc7ad3759eac5c751ece7f67a78CAS | 21210747PubMed |

[63]  Ebina, H. et al. (2013) Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 3, 2510.
| Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus.Crossref | GoogleScholarGoogle Scholar | 23974631PubMed |

[64]  Barton, K.M. et al. (2013) Prospects for treatment of latent HIV. Clin. Pharmacol. Ther. 93, 46–56.
| Prospects for treatment of latent HIV.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhvVGms7rP&md5=4de724e160d06e35d845aeb6bdd5120cCAS | 23212106PubMed |

[65]  Wightman, F. et al. (2012) HDAC inhibitors in HIV. Immunol. Cell Biol. 90, 47–54.
| HDAC inhibitors in HIV.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xkslylug%3D%3D&md5=3ed07032967e0d31d51ddd1943557da3CAS | 22083528PubMed |

[66]  Fass, D.M. et al. (2012) Histone acetylation and deacetylation. In Encyclopedia of Molecular Cell Biology and Molecular Medicine (Second edn). (Meyers, R.A., ed.), pp. 1-47, Wiley-VCH Verlag GmbH & Co. KGaA.

[67]  Archin, N.M. et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207–212.
| Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXisVSnurk%3D&md5=23de052928194b2cb3c637be63135293CAS | 19239360PubMed |

[68]  Contreras, X. et al. (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284, 6782–6789.
| Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXislWrtbc%3D&md5=7ca05915d9a4dee3c06d1d2375e055ecCAS | 19136668PubMed |

[69]  Shan, L. et al. (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491–501.
| Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XjsFGiu7s%3D&md5=ca9f864a3f1fc0a66510734cbad6bf13CAS | 22406268PubMed |

[70]  Bullen, C.K. et al. (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 20, 425–429.
| New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXks12msLg%3D&md5=dc201a07c5214eb1a9438d04187b54b2CAS | 24658076PubMed |

[71]  Archin, N.M. et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485.
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhtFWjtrfP&md5=3232ff25692c00851930a16274cebb9eCAS | 22837004PubMed |

[72]  Elliott, J.H. et al. (2013) The safety and effect of multiple doses of vorinostat on HIV transcription in HIV⁺ patients receiving cART. 2013 Mar 4.

[73]  Archin, N.M. et al. (2014) HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat. J. Infect. Dis. , .
| HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat.Crossref | GoogleScholarGoogle Scholar | 24620025PubMed |

[74]  Rasmussen, T. et al. (2013) Cyclic dosing of panobinostat to reverse HIV-latency: findings from a clinical trial. 2013 Dec.

[75]  Conticello, C. et al. (2012) Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. Int. J. Cancer 131, 2197–2203.
| Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XksV2hu7w%3D&md5=52dcfe8a21cd7a3ffdcafd90958e79e7CAS | 22322883PubMed |

[76]  Xing, S. et al. (2011) Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J. Virol. 85, 6060–6064.
| Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4⁺ T cell model without inducing global T cell activation.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXntFKqs7k%3D&md5=05c6f0eef314c63f487babfe5db3b502CAS | 21471244PubMed |

[77]  Doyon, G. et al. (2013) Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS 27, F7–F11.
| Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhvVClsL3I&md5=732d3a192f57161fbbda71b8850f410cCAS | 22739395PubMed |

[78]  Spivak, A.M. et al. (2014) A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin. Infect. Dis. 58, 883–890.
| A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXjs1Cks7w%3D&md5=dbf54e660d933dd21825125fb97507e0CAS | 24336828PubMed |

[79]  Levy, Y. et al. (2012) Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin. Infect. Dis. 55, 291–300.
| Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XpsVahs7o%3D&md5=fea4d0acd98b2d797812c4c4e6ebd663CAS | 22550117PubMed |

[80]  Vandergeeten, C. et al. (2013) Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121, 4321–4329.
| Interleukin-7 promotes HIV persistence during antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXovFKnt7Y%3D&md5=7563d877bbd755c24d07f1c24ebd1ed3CAS | 23589672PubMed |

[81]  Douek, D.C. (2013) Immune activation, HIV persistence, and the cure. Top Antivir Med 21, 128–132.
| 24225078PubMed |

[82]  Puertas, M.C. et al. (2014) Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS 28, 325–334.
| Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXis1Wks7c%3D&md5=e4f219026054e8fcbebdf7eb9080f758CAS | 24185044PubMed |

[83]  Deeks, S.G. et al. (2013) The end of AIDS: HIV infection as a chronic disease. Lancet 382, 1525–1533.
| The end of AIDS: HIV infection as a chronic disease.Crossref | GoogleScholarGoogle Scholar | 24152939PubMed |

[84]  Garcia, F. et al. (2013) A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci. Transl. Med. 5, 166ra2.
| A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.Crossref | GoogleScholarGoogle Scholar | 23283367PubMed |

[85]  Hansen, S.G. et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523–527.
| Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXmslSrtr0%3D&md5=9bba16c739a85e5e6b461aadd4db63d1CAS | 21562493PubMed |

[86]  Hansen, S.G. et al. (2013) Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104.
| Immune clearance of highly pathogenic SIV infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhsVWqt7%2FO&md5=b3a658a0d6669799c0b0319d3dd7b1e7CAS | 24025770PubMed |

[87]  Eriksson, S. et al. (2013) Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 9, e1003174.
| Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXktlWjtrY%3D&md5=f91b712413178e12d171fbae0ae2cbf4CAS | 23459007PubMed |

[88]  Rouzioux, C. and Richman, D. (2013) How to best measure HIV reservoirs? Curr Opin HIV AIDS 8, 170–175.
| How to best measure HIV reservoirs?Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXlvVWjsLo%3D&md5=f6af919d6c761d199493a2e7c4a4d766CAS | 23564004PubMed |

[89]  Spina, C.A. et al. (2013) An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 9, e1003834.
| An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4⁺ T cells from aviremic patients.Crossref | GoogleScholarGoogle Scholar | 24385908PubMed |